tirzepatide cardiovascular outcomes trial results july 2025 of semaglutide and for patients with type 2 diabetes in clinical practice ❇️ Cardiovascular Outcomes with Tirzepatide

Diabetes spectrum : a publication of the American Diabetes Association

We recommend starting with a low dose and gradually increasing it to minimize side effects such as nausea, stomach pain, or constipation

Insulin Secretion: Enhances both the first and second phases of insulin release in response to glucose

Elevated intracranial pressure is a known headache trigger and is the defining feature of conditions like idiopathic intracranial hypertension

That does not mean the medications are necessarily causing these symptoms but it could suggest that reports of menstrual changes and body temperature fluctuations are worth studying more systematically, she added

Salen G, Shefer S, Batta AK, Tint GS, Xu G, Honda A, et al